NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class (Ascending) | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
81643-9270-01 | 81643-9270 | Floxuridine | Floxuridine | 500.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intra-arterial | June 9, 2022 | In Use | |
65162-0843-06 | 65162-0843 | Capecitabine | Capecitabine | 150.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | March 10, 2017 | Feb. 1, 2024 | In Use |
65162-0844-06 | 65162-0844 | Capecitabine | Capecitabine | 500.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | March 10, 2017 | Feb. 1, 2024 | In Use |
65162-0844-16 | 65162-0844 | Capecitabine | Capecitabine | 500.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | March 10, 2017 | Feb. 1, 2024 | In Use |
65162-0844-50 | 65162-0844 | Capecitabine | Capecitabine | 500.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | March 10, 2017 | Feb. 1, 2024 | In Use |
66530-0249-40 | 66530-0249 | Fluorouracil | Fluorouracil | 50.0 mg/g | Chemotherapy | Antimetabolite | Pyrimidine Analog | Topical | April 11, 2008 | Aug. 31, 2022 | No Longer Used |
67457-0254-30 | 67457-0254 | Azacitidine | Azacitidine | 100.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous, Subcutaneous | May 23, 2016 | In Use | |
16714-0578-01 | 16714-0578 | Azacitidine | Azacitidine | 100.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous, Subcutaneous | Nov. 18, 2022 | In Use | |
25021-0235-50 | 25021-0235 | Gemcitabine Hydrochloride | Gemcitabine | 1.0 g/25mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Dec. 29, 2014 | In Use | |
25021-0235-51 | 25021-0235 | Gemcitabine Hydrochloride | Gemcitabine | 1.0 g/25mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Dec. 15, 2022 | In Use | |
67457-0455-00 | 67457-0455 | Cytarabine | Cytarabine | 100.0 mg/5mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intrathecal, Intravenous, Subcutaneous | Dec. 14, 2011 | No Longer Used | |
67457-0455-52 | 67457-0455 | Cytarabine | Cytarabine | 100.0 mg/5mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intrathecal, Intravenous, Subcutaneous | Dec. 14, 2011 | Oct. 31, 2022 | No Longer Used |
00781-3296-80 | 00781-3296 | Decitabine | Decitabine | 50.0 mg/10mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | March 1, 2020 | In Use | |
00781-3253-94 | 00781-3253 | Azacitidine | Azacitidine | 100.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous, Subcutaneous | Sept. 16, 2013 | Feb. 28, 2025 | In Use |
25021-0231-20 | 25021-0231 | Decitabine | Decitabine | 50.0 mg/20mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Aug. 15, 2018 | March 31, 2023 | In Use |
55150-0393-01 | 55150-0393 | AZACITIDINE | AZACITIDINE | 100.0 mg/4mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous, Subcutaneous | Jan. 3, 2023 | In Use | |
51991-0797-98 | 51991-0797 | Azacitidine | Azacitidine | 100.0 mg/50mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Subcutaneous | Aug. 7, 2017 | Jan. 31, 2024 | In Use |
67457-0452-20 | 67457-0452 | Cytarabine | Cytarabine | 2.0 g/20mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intrathecal, Intravenous, Subcutaneous | Jan. 31, 2012 | Dec. 31, 2022 | No Longer Used |
69097-0905-67 | 69097-0905 | Decitabine | Decitabine | 50.0 mg/10mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Sept. 17, 2021 | In Use | |
00703-5775-01 | 00703-5775 | Gemcitabine | Gemcitabine | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | July 14, 2011 | Jan. 31, 2014 | No Longer Used | |
00703-5778-01 | 00703-5778 | Gemcitabine | Gemcitabine | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | July 14, 2011 | Jan. 31, 2014 | No Longer Used | |
00781-3282-75 | 00781-3282 | Gemcitabine Hydrochloride | Gemcitabine Hydrochloride | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Aug. 27, 2010 | June 30, 2014 | No Longer Used | |
00781-3283-79 | 00781-3283 | Gemcitabine Hydrochloride | Gemcitabine Hydrochloride | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Aug. 27, 2010 | June 21, 2014 | No Longer Used | |
55390-0806-10 | 55390-0806 | Cytarabine | Cytarabine | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous, subcutaneous, intrathecal | June 28, 1996 | July 31, 2013 | No Longer Used | |
55390-0807-10 | 55390-0807 | Cytarabine | Cytarabine | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous, subcutaneous, intrathecal | June 28, 1996 | March 31, 2013 | No Longer Used | |
55390-0809-01 | 55390-0809 | Cytarabine | Cytarabine | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous, subcutaneous, intrathecal | June 28, 1996 | Dec. 31, 2010 | No Longer Used | |
64842-0727-09 | 64842-0727 | CEDAZURIDINE and DECITABINE | INQOVI | 100.0 mg/1, 35.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog + CDA Inhibitor | Oral | Aug. 25, 2020 | In Use | |
55513-0730-01 | 55513-0730 | Denosumab | XGEVA | 120.0 mg/1.7mL | Immunotherapy | Monoclonal Antibody | RANKL | Subcutaneous | Nov. 18, 2010 | In Use | |
55513-0710-01 | 55513-0710 | Denosumab | Prolia | 60.0 mg/mL | Immunotherapy | Monoclonal Antibody | RANKL | Subcutaneous | June 5, 2010 | In Use | |
50242-0210-12 | 50242-0210 | Pralsetinib | Gavreto | 100.0 mg/1 | Chemotherapy | Enzyme Inhibitor | RET, DDR1, TRKC, FLT3, JAK1/2, TRKA, VEGFR2, PDGFRB, FGFR1 | Oral | Sept. 15, 2020 | In Use | |
50242-0210-60 | 50242-0210 | Pralsetinib | Gavreto | 100.0 mg/1 | Chemotherapy | Enzyme Inhibitor | RET, DDR1, TRKC, FLT3, JAK1/2, TRKA, VEGFR2, PDGFRB, FGFR1 | Oral | July 1, 2021 | In Use | |
50242-0210-83 | 50242-0210 | Pralsetinib | Gavreto | 100.0 mg/1 | Chemotherapy | Enzyme Inhibitor | RET, DDR1, TRKC, FLT3, JAK1/2, TRKA, VEGFR2, PDGFRB, FGFR1 | Oral | July 1, 2021 | In Use | |
50242-0210-86 | 50242-0210 | Pralsetinib | Gavreto | 100.0 mg/1 | Chemotherapy | Enzyme Inhibitor | RET, DDR1, TRKC, FLT3, JAK1/2, TRKA, VEGFR2, PDGFRB, FGFR1 | Oral | Sept. 15, 2020 | In Use | |
50242-0210-90 | 50242-0210 | Pralsetinib | Gavreto | 100.0 mg/1 | Chemotherapy | Enzyme Inhibitor | RET, DDR1, TRKC, FLT3, JAK1/2, TRKA, VEGFR2, PDGFRB, FGFR1 | Oral | July 1, 2021 | In Use | |
72064-0210-12 | 72064-0210 | pralsetinib | GAVRETO | 100.0 mg/1 | Chemotherapy | Enzyme Inhibitor | RET, DDR1, TRKC, FLT3, JAK1/2, TRKA, VEGFR2, PDGFRB, FGFR1 | Oral | Sept. 4, 2020 | April 30, 2022 | No Longer Used |
72064-0210-60 | 72064-0210 | pralsetinib | GAVRETO | 100.0 mg/1 | Chemotherapy | Enzyme Inhibitor | RET, DDR1, TRKC, FLT3, JAK1/2, TRKA, VEGFR2, PDGFRB, FGFR1 | Oral | Sept. 4, 2020 | April 30, 2022 | No Longer Used |
72064-0210-90 | 72064-0210 | pralsetinib | GAVRETO | 100.0 mg/1 | Chemotherapy | Enzyme Inhibitor | RET, DDR1, TRKC, FLT3, JAK1/2, TRKA, VEGFR2, PDGFRB, FGFR1 | Oral | Sept. 4, 2020 | April 30, 2022 | No Longer Used |
79802-0200-30 | 79802-0200 | belumosudil | Rezurock | 200.0 mg/1 | Chemotherapy | Rho Kinase Inhibitor | ROCK 1, ROCK2 | Oral | July 16, 2021 | In Use | |
50419-0208-01 | 50419-0208 | Radium Ra 223 dichloride | Xofigo | 30.0 uCi/mL | Chemotherapy | Radiopharmaceutical | Radium 223 | Intravenous | May 20, 2013 | In Use | |
00187-5525-60 | 00187-5525 | Bexarotene | Targretin | 1.0 g/100g | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Topical | June 28, 2000 | In Use | |
00187-5526-75 | 00187-5526 | Bexarotene | Targretin | 75.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | Dec. 29, 1999 | In Use | |
00378-6955-01 | 00378-6955 | Bexarotene | Bexarotene | 75.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | July 9, 2015 | In Use | |
68682-0003-10 | 68682-0003 | Bexarotene | Bexarotene | 75.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | Dec. 17, 2015 | In Use | |
00832-0285-00 | 00832-0285 | Bexarotene | Bexarotene | 75.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | July 25, 2018 | In Use | |
69238-1250-01 | 69238-1250 | Bexarotene | Bexarotene | 75.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | Sept. 4, 2018 | In Use | |
43975-0315-10 | 43975-0315 | Bexarotene | Bexarotene | 75.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | May 10, 2018 | In Use | |
00004-0155-49 | 00004-0155 | Isotretinoin | Accutane | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | May 7, 1982 | Dec. 22, 2010 | No Longer Used | ||
00004-0156-49 | 00004-0156 | Isotretinoin | Accutane | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | May 7, 1982 | Dec. 22, 2010 | No Longer Used | ||
00004-0169-49 | 00004-0169 | Isotretinoin | Accutane | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | May 7, 1982 | Dec. 22, 2010 | No Longer Used | ||
54868-0955-00 | 54868-0955 | Isotretinoin | Accutane | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Aug. 7, 1995 | Dec. 29, 2010 | No Longer Used |
Found 9,752 results in 35 milliseconds — Export these results